SCHEMBL5542896

SCHEMBL5542896

Cc1cc2[nH]c(=O)oc2cc1Cl

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.72
GRIN2D O15399 2/20 0.53
GRIN3B O60391 2/20 0.53
GRIN1 Q05586 2/20 0.53
GRIN2A Q12879 2/20 0.53
GRIN2B Q13224 2/20 0.53
GRIN2C Q14957 2/20 0.53
GRIN3A Q8TCU5 2/20 0.53
NOS1 P29475 4/20 0.53
NOS3 P29474 3/20 0.53
NOS2 P35228 3/20 0.53
TSHR P16473 2/20 0.53
LMNA P02545 1/20 0.53
CYP1A2 P05177 1/20 0.53
ADRA2A P08913 1/20 0.53
THPO P40225 1/20 0.53
BLM P54132 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
LRRK2 Q5S007 1/20 0.42
OGT O15294 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536706 0.93 KMO (0.72) KMOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL17069084 0.84 NOS1 (0.60) KMOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL11256608 0.84 KMO (1.00) KMOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL522196 0.78 NOS1 (0.53) KMOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL5543211 0.78 NOS1 (0.53) KMOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL12420056 0.78 KMO (0.72) KMONOS1NOS3NOS2TSHR
SCHEMBL5536562 0.78 NOS1 (0.53) KMOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL783644 0.78 KMO (0.72) KMONOS1NOS3NOS2TSHR
SCHEMBL11045421 0.78 KMO (0.72) KMONOS1NOS3NOS2TSHR
SCHEMBL5542889 0.78 KMO (0.72) KMOGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KMO 4404/4885GRIN2D 587/4885GRIN3B 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.